IDH1-Mutant Cholangiocarcinoma After First-Line Failure: Ivosidenib or FOLFOX
Progression after first-line gemcitabine-cisplatin-durvalumab in IDH1-mutant cholangiocarcinoma, and whether a better-tolerated targeted drug or a survival-proven chemotherapy regimen goes first.
Daniel O., 61, cut back from long-haul routes to short regional runs eight months ago, not for his health at first but so he could be home for his wife — then, three weeks later, for the reason that actually mattered: a diagnosis of intrahepatic cholangiocarcinoma. He completed six cycles of gemcitabine-cisplatin with durvalumab, tolerated it reasonably, and felt, by his own account, "like I was getting away with something." Today's restaging CT ends that: the dominant hepatic lesion has grown, and a new small deposit has appeared on the peritoneal surface — real progression, not an equivocal read. His genomic testing from diagnosis, filed and mostly forgotten since nothing acted on it at the time, showed an IDH1 R132C mutation, present in roughly 13 percent of intrahepatic cholangiocarcinomas. He's ECOG performance status 1 — some fatigue, but still driving his shortened routes most days — with normal counts and, importantly for what comes next, no residual neuropathy after six cycles of cisplatin. That last detail is the one that keeps oxaliplatin genuinely available to him: a patient who finished platinum-based therapy with numb fingertips would have the second-line decision made for him before anyone debated it, and Daniel didn't.
ClarIDHy enrolled patients in exactly this position — IDH1-mutant cholangiocarcinoma, progressed after first-line therapy — and randomized them to ivosidenib against placebo, finding a real, if modest, progression-free-survival benefit with a materially easier toxicity profile than another round of infusional chemotherapy. Set against that is ABC-06, the trial that actually established a genuine overall-survival benefit for FOLFOX plus supportive care in this same second-line setting; ClarIDHy's own overall-survival analysis, by contrast, was substantially diluted by crossover, since most patients randomized to placebo went on to receive ivosidenib once they progressed. Daniel has said, without being asked twice, that staying functional enough to keep his routes matters to him as much as any number on a chart — a preference the team will have to weigh against two trials that were never designed to be compared to each other directly. ClarIDHy's median progression-free survival came out at roughly 2.7 months for ivosidenib against 1.4 for placebo — a modest absolute gain that reads very differently depending on whether it's measured against ABC-06's own survival curve or against doing nothing further, which is the actual comparator ClarIDHy used and not the one currently on the table for Daniel.
At restaging, deciding what comes after progression
ClarIDHy enrolled exactly this patient — IDH1-mutant cholangiocarcinoma, progressed after first-line therapy — and randomized him to ivosidenib against placebo, not against FOLFOX; the PFS benefit it showed held up cleanly, and ivosidenib is an oral pill with a materially easier day-to-day burden than another infusional regimen. He's told us directly he wants to keep driving his routes; that's not a minor consideration here.
The PFS number is real, but ClarIDHy's overall-survival analysis was badly confounded — most of the placebo arm crossed over to ivosidenib at progression, which mechanically narrows any survival difference regardless of the drug's true effect. ABC-06 is the trial that actually proved a survival benefit in exactly this second-line setting, comparing FOLFOX plus active symptom control against active symptom control alone.
Calling ivosidenib's tolerability decisive assumes FOLFOX's toxicity is worse than it typically is for a patient at ECOG 1 with normal counts — for most patients that's manageable, not prohibitive.
Doesn't need to settle whose trial evidence wins today, because the choice in front of them isn't actually either-or. Start ivosidenib now — it's the better-tolerated option and he's told the team directly that staying functional on his routes matters to him — and bank FOLFOX as the next step if ivosidenib stops working, rather than the reverse. Sequencing this way means neither position has to be wrong for the plan to be right; it just means deciding what he gets first, not what he never gets.
Agreed to start ivosidenib now, with FOLFOX explicitly banked as the next step at any future progression rather than left as an open, undecided question.
Not agreed: how soon to schedule the first ivosidenib-response restaging scan — the oncologist wanted the standard eight-to-ten-week interval; the pharmacist argued for an earlier six-week check specifically because ClarIDHy's own crossover-driven OS confound makes early, honest tracking of his actual response more important than usual, not less.